Contrasting Amylyx Pharmaceuticals (NASDAQ:AMLX) & XORTX Therapeutics (NASDAQ:XRTX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Institutional and Insider Ownership

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Amylyx Pharmaceuticals and XORTX Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
XORTX Therapeutics	N/A	-150.01%	-106.53%

Earnings & Valuation

This table compares Amylyx Pharmaceuticals and XORTX Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	N/A	N/A	-$144.74 million	($1.50)	-8.88
XORTX Therapeutics	N/A	N/A	-$2.66 million	($2.63)	-0.84

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Dividends

Amylyx Pharmaceuticals pays an annual dividend of $1.02 per share and has a dividend yield of 7.6%. XORTX Therapeutics pays an annual dividend of $0.30 per share and has a dividend yield of 13.6%. Amylyx Pharmaceuticals pays out -67.7% of its earnings in the form of a dividend. XORTX Therapeutics pays out -11.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Volatility and Risk

Amylyx Pharmaceuticals has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, XORTX Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Amylyx Pharmaceuticals and XORTX Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1	2	8	1	2.75
XORTX Therapeutics	1	0	0	0	1.00

Amylyx Pharmaceuticals currently has a consensus target price of $23.00, suggesting a potential upside of 72.67%. Given Amylyx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Amylyx Pharmaceuticals is more favorable than XORTX Therapeutics.

Summary

Amylyx Pharmaceuticals beats XORTX Therapeutics on 10 of the 14 factors compared between the two stocks.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

About XORTX Therapeutics

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.